Is Citius Oncology, Inc. CTOR stock halal to invest in?

No, as of August 2026, Citius Oncology, Inc. stock (CTOR) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. To qualify as halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. Citius Oncology, Inc. currently does not meet the threshold for the non-permissible income screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of Citius Oncology, Inc. and discover Shariah compliant alternatives among the halal stocks in the Tabadulat app.

How often is Citius Oncology, Inc. CTOR reviewed for Shariah compliance?

Tabadulat reviews Citius Oncology, Inc. CTOR for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Citius Oncology, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Citius Oncology, Inc. CTOR pass the AAOIFI Non Permissible Income criteria?

No, as of August 2026, Citius Oncology, Inc. stock (CTOR) does not pass the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Citius Oncology, Inc.'s income from non-permissible sources currently exceeds this 5% ceiling, which makes the stock non-compliant on this criterion regardless of how it performs on the other screens. The screen is reassessed monthly, so the status can change when the company releases new financial statements.

Does Citius Oncology, Inc. CTOR pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of August 2026, Citius Oncology, Inc. stock (CTOR) passes the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. This limit ensures shareholders are not materially profiting from riba (interest). Citius Oncology, Inc.'s interest-bearing investments are currently within the 30% threshold. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Citius Oncology, Inc. CTOR pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, Citius Oncology, Inc. stock (CTOR) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Citius Oncology, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Citius Oncology, Inc. CTOR stock?

Citius Oncology, Inc. (CTOR) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a halal investment. If Citius Oncology, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does Citius Oncology, Inc. CTOR pass the AAOIFI Preference Share screen?

Yes, as of August 2026, Citius Oncology, Inc. stock (CTOR) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Citius Oncology, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Citius Oncology, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

CTOR

About

Citius Oncology, Inc.

CTOR

Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment. The primary function of Citius Oncology is to research and develop innovative therapies that aim to enhance the efficacy and safety profiles of current cancer treatments. The company focuses on leveraging new technology platforms and scientific advancements to address unmet medical needs in various types of cancer, impacting both the oncology and pharmaceutical sectors. Citius Oncology's significance in the market revolves around its commitment to advancing cancer therapeutics, which is a critical area due to the disease's widespread impact globally. As a clinical-stage entity, the company plays a crucial role in the pipeline of medical innovation, contributing to potential future options for cancer care. Citius Oncology partners with research institutions and other biopharmaceutical enterprises to push the boundaries of standard oncology treatments. This makes it an influential player in the biotechnology and healthcare sectors, aligning with a broader industry goal to improve patient outcomes in oncology.

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Employees:

Website:

https://www.tenxkeane.com

CTOR

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Citius Oncology, Inc.

About

Citius Oncology, Inc.

CTOR

Frequently asked questions

Is Citius Oncology, Inc. CTOR stock halal to invest in?

How often is Citius Oncology, Inc. CTOR reviewed for Shariah compliance?

Does Citius Oncology, Inc. CTOR pass the AAOIFI Non Permissible Income criteria?

Does Citius Oncology, Inc. CTOR pass the AAOIFI Interest Bearing Investments criteria?

Does Citius Oncology, Inc. CTOR pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for Citius Oncology, Inc. CTOR stock?

Does Citius Oncology, Inc. CTOR pass the AAOIFI Preference Share screen?

Can I buy Citius Oncology (CTOR) stock on Tabadulat?

Open your account.

Deposit.

Screen.